AMLX — Amylyx Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1658551 ·
Last close
$27.52
Market Cap
$3.54B
52W High
$41.14
52W Low
$10.83
ADV30
1,421,494
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -49,658,000 -45,489,000 786,795,000 240,095,000 33,059,000
Jun 2026 0 — -45,693,000 -43,423,000 264,564,000 49,326,000 25,397,000
Mar 2026 0 0 -43,779,000 -41,284,000 293,603,000 229,136,000 20,442,000
Dec 2025 0 0 -36,605,000 -32,999,000 332,645,000 226,651,000 27,386,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-129,883,000
Investing CF
$-409,732,000
Financing CF
$554,646,000
CapEx
$-152,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-881,623,000
Inventory
—
Receivables
$88,000
ST Investments
$528,037,000
EBIT TTM
$-175,735,000
Pretax Income TTM
$-163,149,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -153,291,000 -144,735,000 332,645,000 27,386,000 305,259,000 -123,343,000
Dec 2024 87,371,000 -255,677,000 -301,743,000 193,634,000 28,869,000 164,765,000 -167,647,000
Dec 2023 380,786,000 38,802,000 49,271,000 517,454,000 84,022,000 433,432,000 11,919,000
Dec 2022 22,230,000 -201,341,000 -198,375,000 391,453,000 50,846,000 340,607,000 -179,871,000

TTM Snapshot

Revenues TTM
$4,893,000
NetIncome TTM
$-152,092,000
OpCashFlow TTM
—
Assets (Latest)
$264,564,000
Forward EPS
$-1.09

Max Pain — expiry 2027-12-17

max pain strike: $20.00 · spot: $26.62 · call oi: 2,244 · put oi: 1,136

Peers — same industry

TickerNameMarket CapLastDaily %
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
ABCL AbCellera Biologics Inc. $3.60B $11.03 —
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —

News headlines (Yahoo Finance, 1h cache)

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
2026-11-14 17:00 · Yahoo
Why Amylyx Pharmaceuticals Stock Is Up 6.8% And What's Next
2026-11-08 04:27 · Yahoo
Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results
2026-11-07 23:12 · Yahoo
Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified?
2026-11-07 21:15 · Yahoo
Amylyx Pharmaceuticals Inc (AMLX) Q3 2026 Earnings Call Highlights: $768 Million Cash Position ...
2026-11-07 19:06 · Yahoo
Amylyx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-05 23:52 · Yahoo
Amylyx (AMLX) Q3 2026 Earnings Call Transcript
2026-11-05 19:16 · Yahoo
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
2026-11-05 17:14 · Yahoo
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-05 12:00 · Yahoo
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
2026-11-04 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.